The cumulative incidence of significant gastrooesophageal reflux in patients with oesophageal atresia with a distal fistula-a systematic clinical, pH-metric, and endoscopic follow-up study. J Pediatr Surg

Hospital for Children and Adolescents, University of Helsinki, PO BOX 281, 00029, Helsinki, Finland.
Journal of Pediatric Surgery (Impact Factor: 1.39). 02/2007; 42(2):370-4. DOI: 10.1016/j.jpedsurg.2006.10.010
Source: PubMed


Gastrooesophageal reflux (GER) is common in patients with oesophageal atresia (OA). Complicated GER often manifests itself early after the primary repair (PR) and frequently requires antireflux surgery (ARS). How many patients will be later affected is unknown. We conducted an objective long-term follow-up for the cumulative incidence of OA-associated GER based on pH-metry and histology.
Sixty-one consecutive patients with their native oesophagus, who underwent PR for OA with a distal fistula from 1989 to 2004, were included. These children were grouped according to the Spitz classification with 77% as type I, 20% as type II, and 3% as type III. Significant heart disease, tracheomalacia, or gastric outlet obstruction occurred in 18.0 %, 9.8%, and 17.3% respectively, and a wide gap between esophageal segments occurred in 13.1%. Endoscopy and pH-metry at 1 year were followed up by endoscopy and selective pH-metry at 3, 5, and 10 years. Gastrooesophageal reflux was considered significant (sGER) when a patient underwent ARS, endoscopic biopsies disclosed at least moderate oesophagitis, or when total or preprandial reflux index were greater than 10% or 5%, respectively, with or without long (>5 minutes) reflux periods). Significant GER was considered resolved if, without need for ARS or medication, pH-metry or biopsies returned to normal and the patient was symptomless for at least 3 years.
The incidence of sGER/(number of assessed patients) at 6 months, 1 year, 3 years, 5 years, and 10 years was 16.3% (61), 39.3% (61), 44.2% (52), 51.2 % (43), and 44.4% (27). Overall, 28/61 (45.9%) of patients had sGER, and 18/28 (64.3%) patients underwent ARS. In one patient, sGER resolved during the follow-up.
The number of children with sGER associated with OA more than doubled from 6 months to 1 year after PR. Thereafter, there is a progressive increase in the incidence of sGER with age up to 5 years. Spontaneous resolution of sGER is rare.

1 Follower
6 Reads
  • Source
    • "A ` la différence de la situation habituelle en pédiatrie où la prévalence du RGO diminue après l'a ˆge de la marche, le RGO a tendance a ` persister dans l'AO. Dans une série de 61 enfants opérés a ` la naissance, 39 % présentaient un RGO a ` l'a ˆge de 1 an et 44 % a ` l'a ˆge de 10 ans ; 46 % avaient nécessité une intervention chirurgicale antireflux a ` l'a ˆge de 10 ans [4]. Les conséquences du RGO sont nombreuses (tableau II). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Most of the children operated for esophageal atresia will survive the neonatal period. However, medium-term and late complications are frequent in this population. Gastroesophageal reflux disease is observed in 26 to 75% of the cases and can be responsible for peptic esophagitis, anastomotic stenosis, and Barrett esophagus, which is a risk factor for adenocarcinoma of the esophagus. Dysphagia is frequently observed, sometimes several years after the surgery, affecting up to 45% of children at the age of 5 years. Growth retardation is present in nearly one-third of children at the age of 5 years. Ear, nose, and throat and respiratory complications are also very frequent but tend to improve with time. Tracheomalacia is found in 75% of these children at birth, sometimes responsible for severe complications (malaise, bradycardia). Respiratory symptoms are dominated by chronic cough, wheezing, and infections reported in 29% of the children by the age of 5 years. Restrictive, obstructive syndromes and bronchial hyperactivity can be observed, but usually remain moderate. All these complications can influence the patient's quality of life, which is moderately impaired compared to healthy controls. The high frequency of late sequelae in esophageal atresia justifies regular and multidisciplinary follow-up through adulthood.
    Archives de Pédiatrie 09/2012; 19(9):932–938. DOI:10.1016/j.arcped.2012.06.012 · 0.41 Impact Factor
  • Source
    • "In pediatric patients, esophageal complications of GERD include reflux esophagitis, hemorrhage, stricture, and Barrett’s esophagus. Erosive esophagitis occurs in more than one third of pediatric age patients if GERD-promoting disorders, such as neurological impairment, esophageal atresia, or Down syndrome, are present.6,7 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastroesophageal reflux is a common condition in the pediatric population, with an increasing incidence in the last few years. It can be defined as an effortless retrograde movement of gastric contents into the esophagus related to complex multifactorial pathogenesis, involving anatomical, hormonal, environmental, and genetic factors. In some cases, it may be associated with esophageal or extraesophageal symptoms (heartburn and regurgitation), and is defined as gastroesophageal reflux disease (GERD). The therapeutic approach to gastroesophageal reflux in infants and children is often conservative, including changes in lifestyle (eg, posture and thickening of meals). If these children remain symptomatic after lifestyle changes (nutrition, feeding, and positional modification), or present with clinical red flags (poor weight gain, recurrent respiratory symptoms, or hematemesis) and complications of GERD (esophagitis, bleeding, stricture, Barrett's esophagus, or adenocarcinoma) it may be necessary to set up a proper diagnostic protocol. Proton pump inhibitors have been recommended as the most effective acid suppression therapy for adults and pediatric patients. Esomeprazole, the S-isomer of omeprazole, is the only single-isomer proton pump inhibitor available. The paper assesses the safety and tolerability of esomeprazole in pediatric and adolescent patients.
    Adolescent Health, Medicine and Therapeutics 02/2012; 3:27-31. DOI:10.2147/AHMT.S23193
  • Source
Show more